The efficacy of catheters coated with minocycline and rifampin in the prevention of catheter-related bacteremia in cancer patients receiving high-dose interleukin-2  by Chemaly, R.F. et al.
International Journal of Infectious Diseases 14 (2010) e548–e552Review
The efﬁcacy of catheters coated with minocycline and rifampin in the
prevention of catheter-related bacteremia in cancer patients receiving
high-dose interleukin-2§
R.F. Chemaly a,*, P.S. Sharma a, S. Youssef a, D. Gerber b, P. Hwub, S.S. Hanmod a, Y. Jiang a,
R.Y. Hachema, I.I. Raad a
aDepartments of Infectious Diseases, Infection Control, and Employee Health, Unit 402, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard,
Houston, TX 77030-4009, USA
bMelanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
A R T I C L E I N F O
Article history:
Received 20 February 2009
Received in revised form 17 July 2009
Accepted 10 August 2009
Corresponding Editor: Andy I.M.







S U M M A R Y
High-dose interleukin-2 (HDIL-2) has proven to be an effective treatment for metastatic renal cell
carcinoma and melanoma. Previous studies have shown an increase in catheter-related bacteremia
(CRB) in patients on HDIL-2. The primary objective of this study was to evaluate the effectiveness of
minocycline and rifampin-coated catheters (M/R-C) in reducing CRB in cancer patients on HDIL-2. This
was a retrospective study where non-coated catheters (NC-C) and M/R-C were used for the
administration of HDIL-2 before and after December 2004, respectively. Data collected included
demographics, cancer type, catheter type, antibiotic prophylaxis, and infection rates. A total of 107
episodes of catheter use for HDIL-2 were evaluated in 78 patients (30 episodes in patients withM/R-C vs.
77with NC-C). A total of nine episodes of CRBwere identiﬁed, all in patients with NC-C (M/R-C 0% vs. NC-
C 12%; p = 0.06). Themedian time to bacteremia was 11 days (range 1–315 days). A log-rank test showed
a trend that theM/R-C group had lower probability of getting CRB than the NC-C group (p = 0.06). The use
of M/R-C in patients on HDIL-2 therapy for advanced melanoma and renal cell carcinoma may have
reduced the risk of CRB to nil. CRB still occurred despite antibiotic prophylaxis in patients with NC-C.
 2009 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Patients with advanced melanoma and renal cell carcinoma
(RCC) have a poor prognosis. In early studies, high-dose interleu-
kin-2 (HDIL-2) therapy was found to have clinical efﬁcacy in a
subset of patients with cancer at an advanced stage. Interleukin-2
(IL-2) has played an important role in treating such patients, either
alone or in combination with other chemo/immunotherapeutic
agents and treatment strategies. In multiple clinical trials, IL-2 has
been associated with a low, but consistent, rate of overall response
of approximately 13–17% in metastatic melanoma1–3 and has
consistently produced durable responses in a small percentage of
patients with advanced RCC.4–6 However, the substantial toxicity
and limited efﬁcacy that is associated with IL-2 has narrowed its
application to highly selected patients treated at specialized
centers.7,8§ Presented in part at the 45th Annual Meeting of the Infectious Diseases Society
of America, San Diego, CA, USA, October 4–7, 2007.
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administration of IL-2 have been reported.9,10 Bacterial infections,
mainly catheter-related staphylococcal bacteremia, have been
observed by several investigators.11–15 Fortunately, only a
minority of these infections lead to death.13 However, an increase
in the number and duration of hospitalization occurs. Successful
strategies to prevent or decrease the incidence of catheter-related
staphylococcal bacteremia in patients receiving IL-2 have been
used, including the prophylactic use of intravenous oxacillin,16 and
oral novobiocin and rifampin.17 However, the use of intravenous
oxacillin is associated with added costs and catheter manipula-
tions, and the use of the novobiocin and rifampin regimen has been
associated with intolerability in these patients.
Because the prophylactic use of intravenous oxacillin had been
shown to decrease the frequency of staphylococcal bacteremia in
patients receiving IL-2,13,16 all patients with advanced melanoma
or RCC who were admitted to our center for IL-2-based therapy
over the last 5 years received an antibiotic regimen, mainly
intravenous nafcillin for 48 h, as a preventivemeasure for catheter-
related bacteremia (CRB), although it is not the standard of care in
many other institutions. Since the rate of methicillin-resistant
Staphylococcus aureus (MRSA) infection and colonization is on theses. Published by Elsevier Ltd. All rights reserved.
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activity against MRSA, another additional prophylactic strategy
was needed. After December 2004, the use of long-term silicone
catheters coated with minocycline and rifampin (M/R-C) (Spec-
trum; Cook Critical Care, Bloomington, IN, USA)was recommended
in these patients in our institution, as also recommended by the
published guidelines for the prevention of intravascular catheter-
related infections in high-risk patients when the infection rate
remains high.18 In this retrospective study, we report our
experience with these antibiotic-coated catheters and their impact
on the incidence of CRB when compared to the non-coated ones.
2. Methods
2.1. Patients
Thiswas a retrospective studywhere non-coated catheters (NC-
C) andM/R-C, both non-tunneled, were used for the administration
of HDIL-2; NC-C were used before December 2004 andM/R-C after
December 2004. The study included patients with melanoma or
RCC treated with IL-2 between December 1, 2003 and August 31,
2006. All patients were admitted to our institution and received
antibiotic prophylaxis for up to 48 h after the last dose of IL-2,
mainlywith nafcillin (in 67% of episodes). In addition, insertion site
care remained the same during the study period and consisted of
cleaning the site with 2% chlorhexidine gluconate and 70%
isopropyl alcohol. Data collected included demographics, cancer
type, catheter type, antibiotic prophylaxis, adverse events,
systemic toxicities, and bacteremia rates. We retrospectively
identiﬁed the cases of catheter-related infection from the
microbiology databases, and compared them between the two
groups. We also determined the outcome and complications of the
episodes of catheter-related infections in these patients with RCC
and melanoma treated with IL-2.
2.2. Deﬁnitions
Deﬁnitions were based on the published guidelines for the
management of intravascular catheter-related infections.19 In
summary, catheter colonization was deﬁned as the isolation of 15
colony-forming units (CFU) of any microorganism by semiquan-
titative culture (roll plate method) or 103 CFU by quantitative
culture (e.g., sonication technique) from a catheter tip or
subcutaneous segment in the absence of simultaneous clinical
symptoms; or 10 CFU/ml of any organism from a blood culture
drawn through the catheter during routine surveillance in the
absence of fever. Local catheter-related infection was deﬁned as
exit site infection as demonstrated by purulent drainage from the
catheter site yielding a microorganism, with or without concomi-
tant blood stream infection (BSI), or erythema, tenderness, and
swelling within 2 cm of the catheter exit site, and colonization of
the catheter if removed. CRB was considered probable if the
patient had an indwelling central venous catheter (CVC) with at
least one positive blood culture from the peripheral vein, with
clinical manifestations of infection (i.e., fever, chills, and/or
hypotension), and no apparent source for the BSI except the
catheter, whereby the isolated organism was considered as an
organism likely to cause catheter-related infections (such as
staphylococci, diphtheroids/Corynebacterium, Bacillus spp, Ste-
notrophomonas, Klebsiella, Enterobacter, Acinetobacter, Achro-
mobacter). For patients with a blood culture positive for
coagulase-negative staphylococci, either two positive blood
cultures or a quantitative blood culture with 15 colonies/ml
were required.20 If more than one positive culture was identiﬁed,
they should have been drawn within 48 h of one another and
should have been positive for the samemicrobial organism (samespecies and similar antimicrobial susceptibility proﬁle). CRB was
considered deﬁnite if the patient fulﬁlled all the criteria for
probable CRB plus at least one of the following: a positive
semiquantitative (>15 CFU/catheter segment) or quantitative
(>103 CFU/catheter segment) culturewhereby the sameorganism
(species and antibiogram)was isolated from the catheter segment
and peripheral blood; simultaneous quantitative blood cultures
from the catheter and peripheral vein revealing a ratio>5:1 (CVC
vs. peripheral); indicative differential time to positivity (that is,
the blood culture obtained through the CVC became positive at
least 2 h earlier than a positive simultaneous blood culture
obtained from a peripheral vein).
Response to treatment was deﬁned as the resolution of all
clinical and microbiological manifestations of catheter-related
infection, and failure to treatmentwas deﬁned as persistence of the
clinical signs and symptoms of the infection and positive
microbiological data.
2.3. Statistics
The episodes of catheter use were divided into those usingM/R-
C and those using NC-C. The categorical variables were compared
by Chi-square test or Fisher’s exact test, as appropriate. The
continuous variables were compared byWilcoxon rank sum test as
the data departed fromnormal distribution. The overall probability
for CRBwas estimated byKaplan–Meier approach for the two types
of episodes, respectively, and the two probabilities were compared
by a log-rank test. For each episode, the patientwas followed up for
400 days. For patients whose catheter was removed due to other
reasons during the follow-up time period, their times were
regarded as censored observations. The statistical signiﬁcance was
set at p  0.05. All the statistical analyses were performed using
SAS version 9.1 (SAS Institute Inc., Cary, NC, USA).
3. Results
Seventy-eight consecutive patients treated with HDIL-2-based
therapy were identiﬁed for a total of 107 episodes of catheter use
between December 1, 2003 and August 31, 2006. Most of the
patients who received HDIL-2-based therapy had RCC (61%). In 30
episodes, M/R-C were used, whereas NC-C were used in the
remaining 77 episodes. For these two types of episode, patient
baseline characteristics were evaluated and were all comparable
except for a trend towards higher age in patients with M/R-C
(Table 1). All patients received antibiotic prophylaxis, mainly with
intravenous nafcillin for 48 h after the last dose of IL-2 (67% of the
episodes), followed by clindamycin (15% of episodes), and
levoﬂoxacin (13% of episodes).
A total of nine episodes of CRB were identiﬁed (six were
probable and three deﬁnite), all in patients with NC-C (M/R-C 0%
vs. NC-C 12%; p = 0.06). The nine bacteremia episodes occurred in
seven patients between September 2004 and July 2005, with three
of the episodes occurring before December 1, 2004. The median
time to bacteremia was 11 days (range 1–315 days). There was no
difference between patients with and without bacteremia in the
number of courses of IL-2 and whether nafcillin or another type of
antibiotic was used for prophylaxis (all p > 0.4) (Table 2).
Interestingly, eight out of nine CRB (89%) occurred in patients
with advanced RCC, while only one episode occurred in a patient
with melanoma (p = 0.086). Moreover, in three out the nine
episodes of bacteremia, the blood cultures grew more than one
pathogen. The causative pathogens for CRB included methicillin-
resistant coagulase-negative Staphylococcus (3), Stenotrophomo-
nasmaltophilia (2), MRSA, Pseudomonas aeruginosa, Enterococcus sp,
Flavimonas sp, Citrobacter sp, Escherichia coli and Enterobacter
cloacae (one each). In the nine episodes of bacteremia, patients
Figure 1. Kaplan–Meier estimates of being free from catheter-related bacteremia
for patients who hadminocycline and rifampin-coated catheters (M/R-C) and those
who had non-coated catheters (NC-C) (p = 0.063).
Table 1
Characteristics of the patients who had minocycline and rifampin-coated catheters






(30 episodes) (77 episodes)
n (%) n (%)
Age (years), median
(range)
55 (28–66) 51 (26–66) 0.086
Gender 0.13
Female 7 (23) 30 (39)
Male 23 (77) 47 (61)
Race >0.99
White 26 (87) 67 (87)
Non-white 4 (13) 10 (13)
Type of cancer 0.73
Melanoma 11 (37) 31 (40)
Renal cell carcinoma 19 (63) 46 (60)
Prophylaxis 0.14
Nafcillin 17 (57) 55 (71)
Other antibiotics 13 (43) 22 (29)
Days of catheter stay,
median (range)
55 (5–227) 42 (5–393) 0.81a
Catheter-related
bacteremia
0 (0) 9 (12) 0.06b
a The calculations were only limited to those patients whose catheter was
removed during our study period.
b The p-value was calculated from a two-sided Fisher’s exact test.
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the pathogen(s) recovered from the blood. In addition, there was
one episode of probable catheter-related candidemia (Candida
parapsilosis) in a patient with M/R-C. When including this case in
the analysis, 3% (1/30) of episodes in the M/R-C group involved a
catheter-related infection compared to 12% (9/77) in the NC-C
group (p = 0.28). Kaplan–Meier analysis showed a trend towards
better outcome in the M/R-C group (p = 0.063) (Figure 1).
In addition, two episodes of catheter colonization secondary to
coagulase-negative staphylococci occurred in two patients who
had no signs or symptoms of infection; both had theM/R-C. A third
patient with NC-C had positive blood cultures for S. aureuswith the
same colony counts from the indwelling CVC and peripheral blood
and a simultaneous positive culture for the same organism takenTable 2




did not get CRB
p-Value
(9 episodes) (98 episodes)
n (%) n (%)
Age (years), median
(range)
51 (28–53) 53 (26–66) 0.16
Gender >0.99
Female 3 (33) 34 (35)
Male 6 (67) 64 (65)
Race >0.99
White 8 (89) 85 (87)
Non-white 1 (11) 13 (13)
Type of cancer 0.086
Melanoma 1 (11) 41 (42)
Renal cell carcinoma 8 (89) 57 (58)
Prophylaxis 0.47
Nafcillin 5 (56) 67 (68)
Other antibiotics 4 (44) 31 (32)
Days of catheter stay,
median (range)
42 (10–253) 42 (5–393) 0.47
Type of catheter
M/R-C 0 (0) 30 (31) 0.06
NC-C 9 (100) 68 (69)
M/R-C, minocycline and rifampin-coated catheters; NC-C non-coated catheters.from an infected deep wound on the right arm, which was deemed
to be the source of the bacteremia.
In eight out of the nine episodes, patients had to be admitted to
the hospital for fever and chills and were subsequently diagnosed
with CRB. In one episode, the patientwas already in the hospital for
HDIL-2 therapy. The mean length of stay for these complications
was 6 days (range 3–11 days). In one episode, the patient
developed extravascular complications with soft tissue abscesses
secondary to MRSA; the same pathogen was isolated from blood.
All patients received appropriate intravenous followed by oral
antibiotics, with a mean duration of 14 days (range 8–21 days).
There was no relapse of bacteremia documented and all patients
survived.
4. Discussion
In this study, antimicrobial long-term silicone catheters coated
with minocycline and rifampin showed a trend towards preven-
tion of CRB in cancer patients treated with HDIL-2. The M/R-C not
only prevented staphylococcal and Gram-positive CRB, but also
resulted in the prevention of Gram-negative bacteremia. Such
interventions were not associated with any adverse events or
systemic toxicities.
Bacterial infections, particularly catheter-related staphylococ-
cal bacteremia, are a major complication associated with high-
dose interleukin therapy given alone or in combination with other
treatments in cancer, as well as in other immunocompromised
patients.12–15 Several investigators have reported a high rate of
bacteremia ranging from 19% to 41%, which is usually caused by
staphylococci and often associated with the CVC in immunocom-
promised patients receiving HDIL-2 therapy.12–14,21 This high rate
of staphylococcal infection has been attributed to a defect in
neutrophil chemotaxis caused by interleukin, which is reversible
four weeks after completion of this biotherapy.11 Further data
suggest that IL-2 induces the release of human necrosis factor,
which could be the direct cause of this defect.22,23
Several prophylactic strategies have been applied to prevent or
decrease the incidence of bacteremia, particularly staphylococcal
bacteremia, in patients receiving HDIL-2, including the prophylac-
tic use of intravenous oxacillin16 and oral novobiocin and
rifampin.21 However, the use of intravenous oxacillin is associated
with added cost, catheter manipulation, and particularly the
emergence of oxacillin-resistant staphylococcal organisms, such as
MRSA.24 At our center, a combination of oral antibiotics consisting
of novobiocin and rifampin has been used and shown to decrease
the risk of catheter-related bacteremia associated with HDIL-2
therapy in cancer patients.21 However, this systemic oral antibiotic
R.F. Chemaly et al. / International Journal of Infectious Diseases 14 (2010) e548–e552 e551combination was found to be associated with a high rate (54%) of
nausea and vomiting, and 35% of the patients whowere put on this
prophylaxis could not tolerate these drugs because of the severe
nausea and vomiting.
CVCs impregnated with minocycline and rifampin have been
shown to be highly efﬁcacious in the prevention of CRB in high-risk
critically ill as well as cancer patients.25–31 A recent meta-analysis
of eight prospective randomized controlled studies showed that
M/R-C are safe and effective in reducing the rate of catheter
colonization and catheter-related blood stream infections
(CRBSI).31 In addition, indwelling CVCs impregnated with mino-
cycline and rifampin have been shown to have uniquely prolonged
antimicrobial durability in serum, particularly directed against
staphylococci, which extends to 2 months.29,30 This prolonged
activity has made them highly useful in coating long-term silicone
CVCs used in cancer patients, as opposed to the other FDA
approved antimicrobial catheters associated with short-term
antimicrobial durability against staphylococci, such as the
chlorhexidine–silver sulfadiazine-coated catheters.32,33
Unlike the use of systemic antibiotics, such as intravenous
oxacillin, glycopeptides or oral antibiotics such as rifampin with
novobiocin, the use of M/R-C in the prevention of CRBSI has not
been associated with any local or systemic adverse events or the
emergence of resistant organisms.25–31 Several prospective ran-
domized trials have evaluated the susceptibility of organisms at
the catheter insertion site prior to the insertion of the M/R-C and
after the prolonged use of such catheters, and did not show any
decreased susceptibility.25,26,29,30 Furthermore, several in vitro
studies have shown that prolonged bacterial exposure toM/R-C did
not affect the antimicrobial activity of these catheters.34,35 An
evaluation of the clinical experience of M/R-coated CVCs in bone
marrow transplant recipients at the MD Anderson Cancer Center
over a four-year period that included more than 27 000 catheter
days, showed that staphylococci cultured from the skin insertion
site and the catheter tip remained highly susceptible to
minocycline and rifampin.28 To date, since their approval in
1997, no local or systemic adverse events have been reported or
associated with the use of such catheters in patients worldwide.31
Several studies have evaluated the cost-effectiveness of CVCs
impregnated with minocycline and rifampin and have found them
to be cost-effective and cost-saving.25,27,36,37 Hanna et al. reported
that the use of M/R-C in critically ill cancer patients resulted in a
net saving of at least $1 450 000 annually.27 Marciante et al.
showed that the M/R-coated CVCs were more cost-effective than
other antimicrobial CVCs, particularly if used for a period of two
weeks or longer.36 Shorr et al. showed that the M/R-coated CVCs
were associated with cost savings of $9600 per CRBSI and $81 cost
saving per patient when compared with CVCs coated with
chlorhexidine–silver sulfadiazine.37
On the other hand, a major limitation is the fact that the M/R-
coated catheters are not effective in preventing catheter-related
candidemia, as is evident in other studies,30,38 including this study
where a probable catheter-related candidemia caused by C.
parapsilosis occurred in a patient with an M/R-C. However, given
the fact that this catheter-related candidemia occurred more than
180 days following the insertion of the M/R-C, it might not imply
that these catheters predispose for catheter-related candidemia,
particularly since the antimicrobial durability of the M/R-C
extends to only 50–60 days. Among the limitations of this study
is its retrospective design and small sample size.
In conclusion, with the wide use of IL-2 therapy, particularly in
cancer patients with melanoma and RCC, as well as its potential
use in high-risk patients such as the HIV patient population,39 the
systemic prophylaxis with intravenous antimicrobial therapy,
such as oxacillin or nafcillin, continues to be associated with a
relatively high rate of CRBSI. In this current study, the use ofantimicrobial CVCs coated with minocycline and rifampin in this
patient population showed a trend towards prevention of CRBSI
caused by methicillin-resistant staphylococci and Gram-negative
bacilli, and points to the need for further evaluation in a large
randomized study. Furthermore, the future development of
second-generation antimicrobial CVCs with broad-spectrum anti-
bacterial and antifungal therapy needs to be pursued and
evaluated in clinical trials.
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